announced a worldwide licensing agreement enabling GSK to develop novel medicines for neurodegenerative diseases by utilizing ABL Bio's blood-brain barrier (BBB) shuttle platform, Grabody-B.

The properties of the blood-brain barrier serve a vital protective ... gives GSK access to a platform technology developed by ABL Bio. Specific diseases covered by the pact were not disclosed.

Founder and Chief Scientific Officer of BrainChild Bio. "This designation is a major milestone for the children and families afflicted with these devastating brain tumors and represents a new ...

ABL Bio announced on the 7th that it has signed a technology transfer contract with the British pharmaceutical company GlaxoSmithKline (GSK) for the Blood Brain Barrier shuttle technology known as ...

The blood-brain barrier (BBB) serves as a protective ... in the development of treatments for neurological diseases. ABL Bio's Grabody-B was developed to overcome the limitations of existing ...